INTRODUCTION
The vaccines sector is undergoing a period of growth, making it a more
attractive market to pharmaceutical companies. In addition, changing population
demographics, competition and new technologies are further transforming this
area. Indeed, novel vaccines are anticipated to provide protection against a
much wider spectrum of conditions, including infection by the major nosocomial
pathogens.
SCOPE OF THE REPORT
- Overview of the current vaccine market, describing the key drivers and
resistors of growth
- Descriptions of key players and new contenders in vaccines sector,
detailing their current portfolios and commercial strategies
- Characterization of the clinically-significant nosocomial pathogens and
information regarding the potential vaccine market size for each
- Profiles of pipeline nosocomial vaccines and an evaluation of their market
potential and likely impact
REPORT HIGHLIGHTS
The growth rate for the global vaccines market currently outpaces other
infectious diseases sectors with predicted year-on-year growth of 10-12%,
equating to a market size of approximately $17 billion in 2010, on a par with
antivirals. Datamonitor believes a large proportion of these sales will fall
outside the existing four-company oligopoly. Within the dominant high-volume
pediatric segment, declining birth rates, uncertain market access and intense
competition forces vaccine players to consider a range of new product strategies
with a varying levels of commercial risk. Examples include monoclonal
antibodies, therapeutic vaccines, newer adjuvants and delivery systems. The
niche sector of nosocomial infection vaccines has seen investment by numerous
pharmaceutical companies in recent years, with many products in clinical
development. Datamonitor predicts that peak global sales of an S. aureus
prophylactic vaccine and therapeutic monoclonal antibody could reach $1.8
billion and $2.6 billion respectively.
KEY REASONS TO BUY THIS REPORT
- Gain insight into the current vaccine market, and identify the key players
and emerging novel technologies
- Identify the companies leading the development of nosocomial vaccines and
their strategies and pipeline products
- Recognize the market potential for nosocomial vaccines
| 
View Cart
